Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH
Completed
- Conditions
- PNH
- Registration Number
- NCT03460301
- Lead Sponsor
- Handok Inc.
- Brief Summary
Patients who are positive of PNH-type cells are followed up for the percentage of PNH-type cells regularly for examining how it change.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 233
Inclusion Criteria
- Patients with Commbs' test - negative
- Any patients meeting any of Idiopathic AA/MDS/Patients who had PNH clone size <10%
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time-course changes in the percentage of PNH-type cells in patients who are positive of PNH-type cells during period 5 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of GPI-anchored protein deficiency in PNH-type cells within bone marrow failure syndrome?
How does the presence of PNH-type cells affect the efficacy of standard-of-care treatments for bone marrow failure in Korean populations?
Which biomarkers correlate with the progression of hemolytic PNH in patients with bone marrow failure syndrome as observed in NCT03460301?
What adverse events are associated with PNH-type cell monitoring in long-term observational studies like OPENK?
Are there combination therapies or competitor drugs targeting GPI-anchored proteins for PNH and bone marrow failure syndrome?